-+ 0.00%
-+ 0.00%
-+ 0.00%
Heyu-B (02256) Annexed to the 2026 ENA Conference Announces Preclinical Research Results for the Novel Selective CDK4 Inhibitor ABSK192 Single Drug and Combination Treatment
Share
Listen to the news

Zhitong Finance App News, Heyu-B (02256) announced that the company's subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Pharmaceutical) announced that the preclinical research results of ABSK192, a novel selective CDK4 inhibitor developed independently, were presented in the form of a poster at the 38th EORTC-NCI-AACR Molecular Targets and Cancer Treatment Conference (2026 ENA Conference). This study was selected for the Late-Breaking Abstracts (LBA) program, and Dr. Zhang Nannan, senior director of translational medicine and biomarker research at Heyu Pharmaceutical, demonstrated ABSK192's single-agent activity and broad combination treatment potential in the HR+/HER2 breast cancer model.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending